Search Prime Contracts

75N91025C00051

Definitive Contract

Overview

Government Description
SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE
Awardee
Novomedix
Awarding / Funding Agency
National Cancer Institute (NCI) [HHS - NIH]
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN12 - Health R&D Services; Health Care Services; Applied Research
Place of Performance
San Diego, CA 92126 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Research Type
Small Business Innovation Research Program (SBIR) Phase II
Est. Average FTE
8
Related Opportunity
75N91024R00019
Novomedix was awarded Definitive Contract 75N91025C00051 (75N910-25-C-00051) for Sbir Phase Ii - Enhanced Overall Survival In High-Risk Pediatric Solid Tumors Using A Novel Oral Small Molecule worth up to $2,977,013 by National Cancer Institute in September 2025. The contract has a duration of 2 years and was awarded with a Small Business Total set aside with NAICS 541715 and PSC AN12 via direct negotiation acquisition procedures with 16 bids received.

Status
(Open)

Last Modified 9/30/25
Period of Performance
9/15/25
Start Date
9/14/27
Current End Date
9/14/27
Potential End Date
7.0% Complete

Obligations
$3.0M
Total Obligated
$3.0M
Current Award
$3.0M
Potential Award
100% Funded

Award Hierarchy

Definitive Contract

75N91025C00051

Subcontracts

0

Activity Timeline

Interactive chart of timeline of amendments to 75N91025C00051

Transaction History

Modifications to 75N91025C00051

People

Suggested agency contacts for 75N91025C00051

Competition

Number of Bidders
16
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

Other Categorizations

Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Awardee UEI
XQYMHKGDMU75
Awardee CAGE
4C2X1
Agency Detail
Awarding Office
75N910 NIH NCI
Funding Office
75N910
Created By
hhsmrobinson
Last Modified By
hhspwilkison
Approved By
hhspwilkison

Legislative

Legislative Mandates
None Applicable
Performance District
CA-51
Senators
Dianne Feinstein
Alejandro Padilla
Representative
Sara Jacobs
Modified: 9/30/25